ArticleNature communications2024
De novo production of protoberberine and benzophenanthridine alkaloids through metabolic engineering of yeast.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Metabolic engineering ofaBIOTECH · 2026Article
- Synthesis of the Natural Product Berberine.ACS omega · 2026Article
- Structural Elucidation and Engineering of the (S)-scoulerine 2-O-Methyltransferase Enabling Regioselective Epiberberine Biosynthesis in Coptis chinensis.Plant biotechnology journal · 2026Article
- Chromosomal scale genome assembly of medicinal plant Sophora tonkinensis.BMC genomics · 2026Article
- Engineering Salvia miltiorrhiza hairy roots as a scalable platform for high-yield production of paclitaxel and ginsenoside precursors.Plant communications · 2026Article
- Engineering Yarrowia Lipolytica for De Novo Biosynthesis of Abscisic Acid.Biotechnology journal · 2026Article
- Article
- Benzylisoquinoline Alkaloid Production in Yeast via Norlaudanosoline Improves Titer, Selectivity, and Yield.ACS synthetic biology · 2026Article
- Biosynthesis of benzylisoquinoline alkaloids and its evolution in plants.Plant communications · 2026Review
- Advances in artificial biosynthesis of bioactive plant natural products.Current opinion in biotechnology · 2026Review
- Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.Chinese herbal medicines · 2026Review
- A Modular Chemoenzymatic Cascade Simplifies Divergent Synthesis of Natural and Unnatural Benzylisoquinoline Alkaloids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genome-wide identification and characterization of methyltransferase involved in benzylisoquinoline alkaloids biosynthesis fromChinese herbal medicines · 2026Article
- Review
- Dihydrosanguinarine enhances tryptophan metabolism and intestinal immune function via AhR pathway activation in broilers.Journal of animal science and biotechnology · 2025Article
- A long road ahead to reliable and complete medicinal plant genomes.Nature communications · 2025Review
- Harnessing organelle engineering to facilitate biofuels and biochemicals production in yeast.Journal of microbiology (Seoul, Korea) · 2025Review
- A concise enzyme cascade enables the manufacture of natural and halogenated protoberberine alkaloids.Nature communications · 2025Article
- Advances in the biosynthesis of naturally occurring benzylisoquinoline alkaloids.Frontiers in plant science · 2025Review
- Modeling for understanding and engineering metabolism.QRB discovery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protoberberine alkaloids and benzophenanthridine alkaloids (BZDAs) are subgroups of benzylisoquinoline alkaloids (BIAs), which represent a diverse class of plant-specialized natural metabolites with many pharmacological properties. Microbial biosynthesis has been allowed for accessibility and scalable production of high-value BIAs. Here, we engineer Saccharomyces cerevisiae to de novo produce a series of protoberberines and BZDAs, including palmatine, berberine, chelerythrine, sanguinarine and chelirubine. An ER compartmentalization strategy is developed to improve vacuole protein berberine bridge enzyme (BBE) activity, resulting in >200% increase on the production of the key intermediate (S)-scoulerine. Another promiscuous vacuole protein dihydrobenzophenanthridine oxidase (DBOX) has been identified to catalyze two-electron oxidation on various tetrahydroprotoberberines at N7-C8 position and dihydrobenzophenanthridine alkaloids. Furthermore, cytosolically expressed DBOX can alleviate the limitation on BBE. This study highlights the potential of microbial cell factories for the biosynthesis of a diverse group of BIAs through engineering of heterologous plant enzymes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.